We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Routine Blood Glucose Measurements Can Accurately Estimate HbA1c

By LabMedica International staff writers
Posted on 06 May 2014
Print article
Image: A typical clinical laboratory diabetes analyzer (Photo courtesy of Innovastar).
Image: A typical clinical laboratory diabetes analyzer (Photo courtesy of Innovastar).
Image: The A1CNow monitoring system for glycated hemoglobin (HbA1c) levels (Photo courtesy of Bayer).
Image: The A1CNow monitoring system for glycated hemoglobin (HbA1c) levels (Photo courtesy of Bayer).
Glycated hemoglobin or HbA1c is the standard measurement for assessing glycemic control over time in people with diabetes and blood levels of HbA1c are typically measured every few months in a laboratory.

The relationship between HbA1c and average glucose levels could determine whether HbA1c could be expressed and reported as average glucose in the same units as used in self-monitoring which could increase individuals' motivation to improve diabetes control.

Scientists at the University of Virginia (Charlottesville, VA, USA) working with those at Sanofi-Aventis Deutschland GmbH (Frankfurt, Germany) developed a data-based model that accurately estimates HbA1c using self-monitored blood glucose (SMBG) readings. The computer algorithm they developed was based on a training data set drawn from 379 subjects and then evaluated for accuracy on an independent test data set. The average HbA1c level was 7.6% (± 1.1%), with minimum and maximum values of 5.2% and 12.2%, respectively.

A conceptually new, clinically viable procedure was developed for real-time tracking of average glycaemia from self-monitoring data. The average glucose tracing can then be converted into running estimates of HbA1c, which can be presented to the patient daily. The computational demands of the procedure are low and therefore readily implementable into devices with limited processing power, such as home SMBG meter.

The procedure, tracking average glycaemia and HbA1c in real time, could provide valuable assistance to the daily optimization of diabetes control. The procedure is not intended as a substitute for laboratory assessments of HbA1c and it should be viewed as a surrogate measure that allows convenient tracing of average glucose, readily implementable in a point-of-care SMBG device.

Satish Garg, MD, a professor of medicine and pediatrics at the University of Colorado (Denver, CO, USA) said, “Patients are used to a HbA1c result from their doctor visits, and this study highlights simple estimated HbA1c values from SMBG data. This may become an important tool for improved patient self-management.” The study was published on April 23, 2014, in the journal Diabetes Technology & Therapeutics.

Related Links:

University of Virginia 
Sanofi-Aventis Deutschland GmbH 
University of Colorado


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.